FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590850394> ?p ?o ?g. }

• W2590850394 endingPage "85" @default.
• W2590850394 startingPage "80" @default.
• W2590850394 abstract "PurposeThe effect of adjunctive brivaracetam on health-related quality of life (HRQoL) was assessed in a post-hoc analysis using pooled data from three randomized, double-blind, placebo-controlled Phase III studies in patients with refractory focal seizures (NCT00490035, NCT00464269, and NCT01261325).MethodsThe Patient-Weighted Quality of Life in Epilepsy Questionnaire (QOLIE-31-P) was completed at randomization, and weeks 4, 8 (in two of three studies), and 12 (end of the treatment period). Mean change from baseline to week 12 or early discontinuation, and percentage of patients with clinically meaningful improvement were reported for the placebo and brivaracetam 50, 100, and 200 mg/day groups.ResultsAt baseline, mean QOLIE-31-P scores were similar between treatment groups. At week 12 or early discontinuation, mean (standard deviation) changes from baseline in QOLIE-31-P total score were 2.8 (12.7), 3.0 (14.0), 2.4 (14.0), and 3.0 (12.1) points for the placebo and brivaracetam 50, 100, and 200 mg/day groups, respectively, indicating HRQoL improved slightly over time during the treatment period, but was similar for placebo and brivaracetam groups. All subscale score changes were positive, indicating stable or improved HRQoL over time. The brivaracetam 100 and 200 mg/day groups showed the largest differences compared with placebo in Seizure Worry subscale scores (7.3 and 8.8 vs. 5.0 points). Approximately 40% of patients had improvements in QOLIE-31-P scores beyond the Minimal Important Change (MIC) thresholds. The subgroup of ≥50% focal seizure frequency responders had higher improvements for all treatment arms and all subscales than for those in the overall pooled population.ConclusionIn this post-hoc analysis, adjunctive brivaracetam treatment was shown to be associated with stable or improving overall HRQoL over time, similar to placebo, with modest improvements in subscales sensitive to efficacy, and no deterioration in subscales sensitive to tolerability. These results reflect the known efficacy and tolerability profile of brivaracetam." @default.
• W2590850394 created "2017-03-03" @default.
• W2590850394 creator A5040988869 @default.
• W2590850394 creator A5052959611 @default.
• W2590850394 creator A5070424111 @default.
• W2590850394 creator A5075710054 @default.
• W2590850394 creator A5079889841 @default.
• W2590850394 creator A5081015137 @default.
• W2590850394 date "2017-04-01" @default.
• W2590850394 modified "2023-09-26" @default.
• W2590850394 title "Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis" @default.
• W2590850394 cites W1498758291 @default.
• W2590850394 cites W1572262481 @default.
• W2590850394 cites W1866138264 @default.
• W2590850394 cites W1916788136 @default.
• W2590850394 cites W1964982339 @default.
• W2590850394 cites W1966931416 @default.
• W2590850394 cites W1970608368 @default.
• W2590850394 cites W1974809694 @default.
• W2590850394 cites W1982731331 @default.
• W2590850394 cites W1989934605 @default.
• W2590850394 cites W1990601331 @default.
• W2590850394 cites W1992028227 @default.
• W2590850394 cites W1995505488 @default.
• W2590850394 cites W2001070928 @default.
• W2590850394 cites W2009353129 @default.
• W2590850394 cites W2012369961 @default.
• W2590850394 cites W2021605614 @default.
• W2590850394 cites W2022458589 @default.
• W2590850394 cites W2031797782 @default.
• W2590850394 cites W2051013481 @default.
• W2590850394 cites W2067241131 @default.
• W2590850394 cites W2081712574 @default.
• W2590850394 cites W2082045121 @default.
• W2590850394 cites W2087319194 @default.
• W2590850394 cites W2090276138 @default.
• W2590850394 cites W2095271866 @default.
• W2590850394 cites W2128648744 @default.
• W2590850394 cites W2135808877 @default.
• W2590850394 cites W2150483421 @default.
• W2590850394 cites W2157381015 @default.
• W2590850394 cites W2419659369 @default.
• W2590850394 cites W2472978162 @default.
• W2590850394 doi "https://doi.org/10.1016/j.yebeh.2016.11.031" @default.
• W2590850394 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28236727" @default.
• W2590850394 hasPublicationYear "2017" @default.
• W2590850394 type Work @default.
• W2590850394 sameAs 2590850394 @default.
• W2590850394 citedByCount "7" @default.
• W2590850394 countsByYear W25908503942017 @default.
• W2590850394 countsByYear W25908503942018 @default.
• W2590850394 countsByYear W25908503942020 @default.
• W2590850394 countsByYear W25908503942021 @default.
• W2590850394 countsByYear W25908503942022 @default.
• W2590850394 crossrefType "journal-article" @default.
• W2590850394 hasAuthorship W2590850394A5040988869 @default.
• W2590850394 hasAuthorship W2590850394A5052959611 @default.
• W2590850394 hasAuthorship W2590850394A5070424111 @default.
• W2590850394 hasAuthorship W2590850394A5075710054 @default.
• W2590850394 hasAuthorship W2590850394A5079889841 @default.
• W2590850394 hasAuthorship W2590850394A5081015137 @default.
• W2590850394 hasBestOaLocation W25908503941 @default.
• W2590850394 hasConcept C118552586 @default.
• W2590850394 hasConcept C126322002 @default.
• W2590850394 hasConcept C142724271 @default.
• W2590850394 hasConcept C159110408 @default.
• W2590850394 hasConcept C168563851 @default.
• W2590850394 hasConcept C204243189 @default.
• W2590850394 hasConcept C204787440 @default.
• W2590850394 hasConcept C27081682 @default.
• W2590850394 hasConcept C2778186239 @default.
• W2590850394 hasConcept C2778715236 @default.
• W2590850394 hasConcept C2779951463 @default.
• W2590850394 hasConcept C3018162438 @default.
• W2590850394 hasConcept C67761136 @default.
• W2590850394 hasConcept C71924100 @default.
• W2590850394 hasConceptScore W2590850394C118552586 @default.
• W2590850394 hasConceptScore W2590850394C126322002 @default.
• W2590850394 hasConceptScore W2590850394C142724271 @default.
• W2590850394 hasConceptScore W2590850394C159110408 @default.
• W2590850394 hasConceptScore W2590850394C168563851 @default.
• W2590850394 hasConceptScore W2590850394C204243189 @default.
• W2590850394 hasConceptScore W2590850394C204787440 @default.
• W2590850394 hasConceptScore W2590850394C27081682 @default.
• W2590850394 hasConceptScore W2590850394C2778186239 @default.
• W2590850394 hasConceptScore W2590850394C2778715236 @default.
• W2590850394 hasConceptScore W2590850394C2779951463 @default.
• W2590850394 hasConceptScore W2590850394C3018162438 @default.
• W2590850394 hasConceptScore W2590850394C67761136 @default.
• W2590850394 hasConceptScore W2590850394C71924100 @default.
• W2590850394 hasFunder F4320337846 @default.
• W2590850394 hasLocation W25908503941 @default.
• W2590850394 hasLocation W25908503942 @default.
• W2590850394 hasOpenAccess W2590850394 @default.
• W2590850394 hasPrimaryLocation W25908503941 @default.
• W2590850394 hasRelatedWork W2039865683 @default.
• W2590850394 hasRelatedWork W2123292389 @default.
• W2590850394 hasRelatedWork W2145537131 @default.

• next